NCT06878144

Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project

MD Anderson Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project (Deciphering Immunopathogenesis of MUCORmycosis to ADVANCE Risk Stratification, Diagnosis and Management of the Disease)

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 300 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

To collect data and samples from participants with cancer who also have invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection.

Detailed description

Primary Objective: To establish MD Anderson Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project. * To prospectively identify, collect, and store all isolates causing proven or probable MCM in adult high-risk cancer participants. * To prospectively identify, collect, and store relevant host samples from high-risk participants developing proven or probable MCM, along with relevant biospecimens from three control groups. * To comprehensively annotate clinical specimens and provide information regarding the course and outcome of all MCM cases and controls. OUTLINE: This is an observational study. Patients are assigned to 1 of 4 groups. GROUP M: Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study. GROUP A: Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study. GROUP B: Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study. GROUP C: Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study.

Conditions

• Mucormycosis

Interventions

Type	Name	Description
BEHAVIORAL	Mucormycosis	Tell the study team about any symptoms or side effects you have, follow study directions, and come to all study appointments (or contact the study team to reschedule).

Timeline

• Start date: 2025-09-30
• Primary completion: 2030-12-31
• Completion: 2032-12-31
• First posted: 2025-03-14
• Last updated: 2025-09-08

Locations

1 site across 1 country: United States